GCT Announces the valuable addition to its U.S. Clinical Operations Team

As of the beginning of 2018 GCT has appointed Michael Wamil, J.D., M.S., as Director of Clinical Operations, U.S., to lead and expand the company’s therapeutic and service portfolio.

Michael brings over 7 years of progressively responsible pharmaceutical and contract research organization (CRO) clinical monitoring, regulatory, project management and consulting experience combined with working knowledge in a variety of therapeutic areas, including CNS, Oncology, Infectious Disease and General Medicine. He will be based in Princeton, New Jersey.

As the development of novel pharmaceuticals, biosimilars, medical devices and diagnostics continues to expand in the U.S. and around the world; our multi-national team is well positioned to offer clients exceptional clinical project management services and solutions. The enhancement of our U.S. team presents a tremendous advantage to companies that wish to collaborate with GCT as we are a truly global clinical study team, with coverage in the United States, Central and Eastern Europe, Russia and India.

About Global Clinical Trials, LLC

GCT is a global CRO headquartered in Princeton, NJ, USA, offering full-service clinical trial support and solutions across the U.S., Central and Eastern Europe, Russia, and India since 2001. Key areas of expertise include CNS, Oncology, Ophthalmology, Reproductive Health, Gastroenterology, Rare Diseases, and Medical Devices.

GCT provides a comprehensive range of services to successfully complete your clinical study, from feasibility analysis and site selection, regulatory strategy and support, document translation and cultural adaptation, investigator meeting planning and hosting, to global and regional project management, investigative site administration, clinical monitoring, quality assurance and quality control, auditing, contracts and payments management, safety support, warehousing and logistics.

Since its inception, GCT remains focused on its founding principle that all of our clients and partners deserve, and should expect, the highest level of excellence, transparency and clarity of data when they choose to collaborate with us for their clinical development needs.